<DOC>
	<DOC>NCT00962026</DOC>
	<brief_summary>This study is being done to see if an investigational drug called rilonacept is safe to use in patients with type 1 diabetes, and if it can slow the loss of the body's ability to secrete insulin in patients who are still able to make a small amount of insulin.</brief_summary>
	<brief_title>Rilonacept in Diabetes Mellitus Type 1: Safety Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<criteria>Within 5 years of diagnosis of type 1 diabetes Between the ages of 16 to 45 years Have at least one diabetesrelated autoantibody present Have mean Cpeptide level &gt; 0.2 nmol/L on a mixed meal tolerance test Be taking insulin Complete written informed consent Taking inhaled or oral steroids (for example Advair, Orapred) Have an active infection Have serologic evidence of HIV, Hepatitis C, Hepatitis C, or tuberculosis Have ongoing use of medications known to affect glucose tolerance Have a live vaccine 90 days prior to, or during this study Taking any other experimental medication within the past 28 days Have prior treatment with rilonacept Have any complicating medical issues or abnormal clinical laboratory blood counts or results that interfere with study conduct; history of malignancies Pregnant or lactating females Males and females unwilling to use an acceptable method of contraception for the duration of the study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Interleukin 1</keyword>
	<keyword>Type 1 diabetes mellitus</keyword>
	<keyword>Rilonacept</keyword>
	<keyword>Arcalyst</keyword>
</DOC>